Dr PennyStock Free Forums
January 22, 2018, 10:57:43 PM *
Welcome, Guest. Please login or register.

Login with username, password and session length
News:
   Home   Help Search Login Register  
Pages: [1]   Go Down
  Print  
Author Topic: ARLZ - Aralez Pharmaceuticals, Inc. - NASDAQ  (Read 1093 times)
0 Members and 1 Guest are viewing this topic.
Vegas
Gold Member
******
Offline Offline

Gender: Male
Posts: 4283



« on: March 28, 2016, 11:09:17 AM »


Daily Chart:  http://stockcharts.com/h-sc/ui?s=ARLZ&p=D&b=5&g=0&id=p11659626820

Weeklt Chart:  http://stockcharts.com/h-sc/ui?s=ARLZ&p=W&b=5&g=0&id=p74425084151

News:  http://finance.yahoo.com/q/h?s=ARLZ+Headlines

Business Summary:  Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada, Ireland, and the United States. The company engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It offers Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks with or without aura in adults; Fiorinal and Fiorinal C for the relief of tension type headaches; Soriatane, a retinoid, an aromatic analog of vitamin A for the treatment of severe psoriasis and other disorders of keratinization; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome.

The company also markets NeoVisc, a sodium hylauronic solution; Uracyst, a sodium chondroitin sulfate; Durela, a tramadol hydrochloride; Proferrin, a heme iron polypeptide; Resultz, a isopropyl myristate; Collatamp G, a collagen-gentamycin; and a portfolio of eight products targeted for the areas of gastroenterology and women’s health. In addition, it develops YOSPRALA 81/40 and 325/40 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have completed Phase III clinical development in the United States; and Bilastine, an antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria. Further, the company’s out-licensed products include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. Aralez Pharmaceuticals Inc. is headquartered in Milton, Canada.

Website:  http://aralez.com/
Logged

♦♦♦ Give me control of a nations money supply, and I care not who makes it’s laws... Mater Amschel Rothschild ♦♦♦
Vegas
Gold Member
******
Offline Offline

Gender: Male
Posts: 4283



« Reply #1 on: March 28, 2016, 11:10:56 AM »


Aralez Announces FDA Acceptance of New Drug Application for YOSPRALA

March 28, 2016

Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has acknowledged acceptance of the New Drug Application ("NDA") for its investigational candidate, YOSPRALA ™ (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. The FDA Prescription Drug User Fee Act ("PDUFA") goal date for a decision is September 14, 2016 .

"The acceptance of our NDA for YOSPRALA marks an important and exciting step toward approval of this product," said Adrian Adams , Chief Executive Officer of Aralez. "We look forward to working with the FDA during the review process in order to bring YOSPRALA to market as quickly as possible."

http://finance.yahoo.com/news/aralez-announces-fda-acceptance-drug-110000019.html
Logged

♦♦♦ Give me control of a nations money supply, and I care not who makes it’s laws... Mater Amschel Rothschild ♦♦♦
Vegas
Gold Member
******
Offline Offline

Gender: Male
Posts: 4283



« Reply #2 on: April 09, 2016, 07:00:09 PM »


An Overview Of The Pinch With The Technicals Annotated In Blue

A Gain Of 26%


Logged

♦♦♦ Give me control of a nations money supply, and I care not who makes it’s laws... Mater Amschel Rothschild ♦♦♦
Pages: [1]   Go Up
  Print  
 
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.8 | SMF © 2006-2008, Simple Machines LLC | Sitemap Valid XHTML 1.0! Valid CSS!
Page created in 0.08 seconds with 25 queries. (Pretty URLs adds 0.009s, 2q)